Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vera Therapeutics, Inc. - Class A Common Stock
(NQ:
VERA
)
41.92
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vera Therapeutics, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
January 25, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Why Vera Therapeutics Stock Bolted Higher This Week
January 22, 2023
Vera's stock gained a noteworthy 49% this week.
Via
The Motley Fool
5 Cheapest Health Care Stocks You Should Think About
January 13, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
January 12, 2023
From
The Schall Law Firm
Via
Business Wire
What 4 Analyst Ratings Have To Say About Vera Therapeutics
January 04, 2023
Via
Benzinga
Top 5 Health Care Stocks That May Surge
January 10, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 05, 2023
On Thursday, 63 companies set new 52-week lows.
Via
Benzinga
Dow Gains 150 Points After Fed Minutes
January 04, 2023
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting.
Via
Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 04, 2023
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 04, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
January 04, 2023
On Wednesday, 35 companies reached new 52-week lows.
Via
Benzinga
Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply
January 04, 2023
U.S. stocks extended gains midway through trading, with the Dow Jones gaining around 250 points on Wednesday ahead of the release of minutes from the Fed's meeting.
Via
Benzinga
These 2 Nasdaq Biotechs Are Making Big Moves Wednesday
January 04, 2023
The binary nature of biotech investing is making itself obvious from recent study results.
Via
The Motley Fool
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
January 04, 2023
The "devil is in the details" when it comes to comparing data across studies.
Via
Investor's Business Daily
US Stocks Open Higher Ahead Of Fed Minutes; Dow Rises 100 Points
January 04, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 04, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
January 04, 2023
Via
Benzinga
Why Oblong Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket
January 04, 2023
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares rose 63.2% to $0.4201 in pre-market trading after dropping 8% on Tuesday. Elys Game Technology and Cloakbook were recently granted a license to...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 04, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study
January 04, 2023
Via
Benzinga
Vera Therapeutics, Phathom Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
January 04, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Tesla, Amazon, Apple, Aurinia Pharma, Vera Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today
January 03, 2023
Major Wall Street indices closed in the red on Tuesday, the first trading day of 2023, as concerns over rising rates and inflation still seem to drive investor sentiments.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 03, 2023
Via
Benzinga
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
January 03, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Present at Upcoming Investor Conferences
November 22, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
November 17, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney
November 05, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week
October 17, 2022
From
Vera Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.